Psychedelic Spotlight Report: “Compass Pathways Sued for Stealing Trade Secrets”
Cannabis Law Report
AUGUST 10, 2022
To explain the embattled patent, essentially, Compass wants to explore whether combining psilocybin with a drug such as ketanserin, a 5-HT2A antagonist —which theoretically would abort a hallucination before it begins— would be equally effective in treating depression.
52 
Let's personalize your content